Zeteletinib
Zeteletinib[edit | edit source]
Zeteletinib is a small molecule inhibitor that targets specific tyrosine kinases involved in various cellular processes, including cell growth, differentiation, and metabolism. It is primarily being investigated for its potential use in the treatment of certain types of cancer.
Mechanism of Action[edit | edit source]
Zeteletinib functions by inhibiting the activity of specific tyrosine kinase receptors that are often overexpressed or mutated in cancer cells. By blocking these receptors, Zeteletinib can interfere with the signaling pathways that promote tumor growth and survival. This makes it a promising candidate for targeted cancer therapy.
Clinical Development[edit | edit source]
Zeteletinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various types of cancer. These trials are designed to determine the optimal dosing, assess potential side effects, and establish the therapeutic benefits of the drug.
Potential Applications[edit | edit source]
The primary focus of Zeteletinib's development is in the treatment of cancers that exhibit aberrant tyrosine kinase activity. This includes certain types of leukemia, lung cancer, and other solid tumors. Researchers are also exploring its use in combination with other chemotherapeutic agents to enhance its effectiveness.
Side Effects[edit | edit source]
As with many targeted therapies, Zeteletinib may cause side effects, which can vary depending on the individual and the dosage. Common side effects observed in clinical trials include fatigue, nausea, and skin rashes. More serious adverse effects are being closely monitored during the trials.
Future Directions[edit | edit source]
Ongoing research aims to better understand the full potential of Zeteletinib in cancer therapy. This includes exploring its use in combination with other treatments, identifying biomarkers for patient selection, and investigating its effects on different cancer subtypes.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
